Education
About Us
Working with TipRanks
Follow Us
PAVmed Inc (PAVM)
NASDAQ:PAVM
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.13Last Year’s EPS
-2.62Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 24, 2025
|% Change Since: -7.41%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a company stabilizing its operations with strategic transformations and strong growth in its subsidiaries. Lucid Diagnostics shows promising revenue growth and insurance breakthroughs, while Veris Health secures financing and strategic partnerships. However, challenges with debt restructuring and dependency on further financing present ongoing concerns.Company Guidance
During PAVmed's Fourth Quarter 2024 Business Update Conference Call, key metrics and guidance were discussed, showcasing the company's robust progress and strategic positioning. Lucid Diagnostics reported $1.2 million in revenue with a record test volume of 4,042 EsoGuard tests, marking a 45% growth quarter-on-quarter. Additionally, a significant milestone was achieved with Highmark Blue Cross Blue Shield in New York establishing the first positive commercial insurance coverage policy for EsoGuard. PAVmed's strong financial restructuring was highlighted, including the deconsolidation of Lucid Diagnostics and restructuring of convertible debt, which preserved PAVmed's NASDAQ listing. Veris Health secured $2.4 million in private placement financing and a $1.8 million NIH grant, positioning it well for the regulatory process of its implantable physiologic monitor. Furthermore, PAVmed's balance sheet was strengthened, with a strategic transformation supporting a sustainable future and a diversified life sciences portfolio.Lucid Diagnostics Revenue Growth
Lucid Diagnostics generated $1.2 million in revenue and achieved a 45% growth quarter-on-quarter in test volume, with over 4,000 tests conducted.
Insurance Coverage Breakthrough
Highmark Blue Cross Blue Shield in New York established the first positive commercial insurance coverage policy for EsoGuard.
NCCN Guideline Update
The National Comprehensive Cancer Network updated its clinical practice guideline to include esophageal precancer screening, which is expected to drive positive commercial insurance coverage decisions.
Veris Health Private Placement
Veris Health completed a private placement financing with gross proceeds of $2.4 million at a $35 million pre-money valuation.
NIH Grant for Veris Health
Veris Health secured a $1.8 million non-dilutive two-year NIH grant to advance their strategy.
Ohio State University Partnership
Extended pilot program with OSU's James Cancer Center and anticipation of a long-term commercial and strategic partnership.
---
PAVM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PAVM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 24, 2025 | $0.81 | $0.80 | -1.23% |
| Nov 14, 2024 | $1.02 | $1.09 | +6.86% |
| Aug 13, 2024 | $0.80 | $0.74 | -7.50% |
| May 14, 2024 | $1.92 | $2.22 | +15.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does PAVmed Inc (PAVM) report earnings?
PAVmed Inc (PAVM) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is PAVmed Inc (PAVM) earnings time?
PAVmed Inc (PAVM) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PAVM EPS forecast?
PAVM EPS forecast for the fiscal quarter 2025 (Q1) is -0.13.
---